Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit You

Showing results (11-20 of 141) with videos related to

Pageof 15
Sort By:
JCO Clinical Cancer Informatics|April 19, 2023
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 TrialOlivier Colomban, Andrew Clamp, Adrian Cook, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2011
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulationInes Paule, Michel Tod, Emilie Hénin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2015
Aggregated adverse-events outcomes in oncology phase III reports: A systematic reviewDenis Maillet, Hui K Gan, Jean-Yves Blay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic reviewJulien Péron, Denis Maillet, Hui K Gan, et al.
Therapeutic Drug Monitoring|July 16, 2019
Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal StandardAurélien Millet, Dorothée Lebert, Guillaume Picard, et al.
Bulletin Du Cancer|December 17, 2025
Gestational trophoblastic diseases and neonatal choriocarcinomaCécile Faure-Conter, Angelique Rome, Daniel Orbach, et al.
Critical Reviews in Oncology/Hematology|April 10, 2007
Contribution of modelling chemotherapy-induced hematological toxicity for clinical practiceDiane Testart-Paillet, Pascal Girard, Benoit You, et al.
The Oncologist|February 3, 2019
Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over TimeOlivia Le Saux, Claire Falandry, Hui K Gan, et al.
Breast Cancer Research and Treatment|March 23, 2016
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patientsEmilie Hénin, Christophe Meille, Dominique Barbolosi, et al.
Clinical Genitourinary Cancer|December 28, 2018
Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct SyndromeElise Bonnet, Sophie Tartas, Anne Lazareth, et al.
Pageof 15

Showing results (11-20 of 141) with videos related to

Sort By:
Pageof 15
JCO Clinical Cancer Informatics|April 19, 2023
Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 TrialOlivier Colomban, Andrew Clamp, Adrian Cook, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2011
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulationInes Paule, Michel Tod, Emilie Hénin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2015
Aggregated adverse-events outcomes in oncology phase III reports: A systematic reviewDenis Maillet, Hui K Gan, Jean-Yves Blay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic reviewJulien Péron, Denis Maillet, Hui K Gan, et al.
Therapeutic Drug Monitoring|July 16, 2019
Determination of Cetuximab in Plasma by Liquid Chromatography-High-Resolution Mass Spectrometry Orbitrap With a Stable Labeled 13C,15N-Cetuximab Internal StandardAurélien Millet, Dorothée Lebert, Guillaume Picard, et al.
Bulletin Du Cancer|December 17, 2025
Gestational trophoblastic diseases and neonatal choriocarcinomaCécile Faure-Conter, Angelique Rome, Daniel Orbach, et al.
Critical Reviews in Oncology/Hematology|April 10, 2007
Contribution of modelling chemotherapy-induced hematological toxicity for clinical practiceDiane Testart-Paillet, Pascal Girard, Benoit You, et al.
The Oncologist|February 3, 2019
Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over TimeOlivia Le Saux, Claire Falandry, Hui K Gan, et al.
Breast Cancer Research and Treatment|March 23, 2016
Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patientsEmilie Hénin, Christophe Meille, Dominique Barbolosi, et al.
Clinical Genitourinary Cancer|December 28, 2018
Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct SyndromeElise Bonnet, Sophie Tartas, Anne Lazareth, et al.
Pageof 15